In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals are going to be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "incorporate-on" therapy. In Section https://abbv-744drugdevelopmentpr70235.ourcodeblog.com/32185198/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies